Acadia Healthcare EVP Brian Farley Sells 1,770 Shares at $34.51 Per Share

Acadia Healthcare Executive Brian Farley Conducts Open Market Share Sale

On July 26, 2026, Brian Farley, Executive Vice President, Chief Legal and Administrative Officer and Secretary at Acadia Healthcare Company, Inc., sold 1,770 shares of common stock in an open market transaction. The regulatory disclosure filed on July 27, 2026, confirms the sale price of $34.51 per share. This sale represents standard insider trading activity by a senior executive of the Florida-based behavioral healthcare company, which operates inpatient and outpatient psychiatric and substance use disorder treatment facilities across the U.S.

After this transaction, Farley's direct beneficial ownership decreased to 135,982 shares. The filing indicates these shares are held in direct ownership form, with no indirect beneficial ownership noted. This substantial stake highlights Farley's continued financial alignment with Acadia Healthcare’s performance and shareholder interests.

Details of the Transaction and Ownership Effects

The July 26, 2026 sale involved 1,770 shares sold via an open market transaction, identified as a "F" transaction in regulatory filings, which denotes an open market disposition. The $34.51 per share price reflects the market value at the time of sale. Although the filing does not specify aggregate proceeds, the transaction generated approximately $61,081.

This sale accounts for less than 1.3% of Farley's total direct beneficial ownership. Retaining 135,982 shares signifies a meaningful investment in the company. As a senior executive overseeing legal and administrative functions, Farley's ongoing shareholding is consistent with typical executive compensation and benefit structures. The filing shows no restrictions or special conditions related to future sales.

Regulatory Filing and Compliance Information

The sale was disclosed via an SEC Form 4 filing, mandated under Section 16(a) of the Securities Exchange Act of 1934 for officers, directors, and significant shareholders. Farley signed the form on July 27, 2026, one business day after the transaction, aligning with SEC reporting timelines that require filings within two business days.

The filing lists Farley's address as 4020 Aspen Grove Drive, Suite 900, Franklin, Tennessee 37067, and confirms his executive titles. It notes his Section 16 reporting obligations, confirming his status as a covered insider. There was no amendment to prior filings, nor references to any Rule 10b5-1(c) trading plans, indicating this was a discretionary open market sale rather than a prearranged transaction.

Leadership Role and Insider Shareholding at Acadia Healthcare

Brian Farley’s role as Executive Vice President, Chief Legal and Administrative Officer and Secretary places him in Acadia Healthcare’s senior leadership, responsible for legal affairs, regulatory compliance, and administrative operations. His ownership of 135,982 shares post-sale underscores a significant personal financial interest in the company’s long-term success.

The filing does not disclose whether other insiders traded shares around the same date or provide historical insider trading comparisons. Investors tracking insider transactions at Acadia Healthcare can use these disclosures to gauge management confidence and capital allocation priorities. All such filings are publicly accessible via the SEC EDGAR database.

Market Overview and Behavioral Health Industry Context

Acadia Healthcare Company, Inc. is a leading U.S. provider of behavioral health and addiction treatment services, operating inpatient psychiatric hospitals, residential treatment centers, and outpatient clinics. The $34.51 per-share sale price reflects the market conditions for ACHC stock on July 26, 2026.

The behavioral health sector has seen dynamic changes recently, including rising demand for mental health services, shifting reimbursement models, and increased regulatory oversight. Insider share transactions may reflect executives’ views on company prospects, but individual sales can also be influenced by personal financial planning and should not be interpreted as definitive indicators of company outlook without further context.

SEC Filing Accuracy and Documentation Standards

The Form 4 filing complies with SEC requirements, detailing transaction codes, dates, share quantities, prices, and resulting ownership. The form confirms it was filed by a single reporting person and shows no indication that Farley is exempt from Section 16 obligations or operating under a Rule 10b5-1 trading plan.

The filing includes a certification warning about the legal consequences of false statements under federal law. Farley signed the document on July 27, 2026, certifying its accuracy. The Form 4 is publicly available through the SEC’s EDGAR system for investors and analysts.

Investor Insights and Monitoring Insider Activity

Investors in ACHC stock or those considering investment may find insider trading disclosures useful for due diligence. While insider buying or selling can signal management sentiment, transactions should be assessed alongside company fundamentals, market trends, and insider personal circumstances. The SEC mandates prompt reporting of such trades, accessible via EDGAR.

The immediate market impact of Farley’s sale is not detailed in public records. No information on concurrent market movements or analyst responses was provided. Investors can track insider activity at Acadia Healthcare through SEC filings or third-party financial data services that aggregate insider trading disclosures, aiding in understanding leadership’s perspective on shareholder value.